Hepatocellular Cancer Market: 67 Drugs in the Pipeline says New Report

Dec. 14, 2010 - PRLog -- The report “Stakeholder Opinions: Hepatocellular Cancer” available at http://www.piribo.com/publications/diseases_conditions/cancer/stakeholder_opinions_hepatocellular_carcinoma.html analyses Hepatocellular cancer (HCC) the fifth and seventh most common cancer in men and women respectively. The majority of patients with HCC are diagnosed with advanced-stage disease and have existing liver damage. The only approved treatment for late-stage disease is Nexavar which is not curative.

Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large patient population and the lack of effective agents are driving R&D interest. The majority of pipeline drugs are molecular targeted therapies (MTTs) and their incorporation into treatment will improve both patient outcomes and commercial potential.

Chemotherapy is rarely used in hepatocellular cancer (HCC) as it is associated with low response rates. Regional therapies for early-stage patients have a high exclusion criteria and curative surgery is associated with relapse rates as high as 21.8%. Novel therapies are needed to improve survival rates in both early and late stage disease.

There are currently 67 drugs in the pipeline, which is dominated by molecular targeted therapies (71%) and cytotoxic therapies (18%). Competition of late-phase pipeline drugs for first approval in HCC is fierce.

The report “Stakeholder Opinions: Hepatocellular Cancer” is available from Piribo: http://www.piribo.com/publications/diseases_conditions/ca...

Piribo product ID: DAT05853

About Piribo
http://www.piribo.com/publications/diseases_conditions/ca... Piribo is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.

# # #

About Piribo.
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.